Profound Medical Corporation (PROF)

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies...

Form 8-K - Current report

Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) --  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Form S-3 - Registration statement under Securities Act of 1933

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Profound Medical Reports Strong First Quarter 2026 Financial Results

– Quarterly results marked by 104% revenue growth and improved operating performance – – Company issues...

Why Medtech Giants Are Quietly Paying Up for AI Diagnostics

Why Medtech Giants Are Quietly Paying Up for AI Diagnostics PR Newswire VANCOUVER, BC, April 29, 2026...

Form 8-K - Current report

Profound Medical to Release First Quarter 2026 Financial Results on May 7 – Conference Call to Follow

TORONTO, April 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Form 8-K - Current report

Profound Medical to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, April 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the...

Form 8-K - Current report